2016/09/29 - Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced positive top-line results from its Phase IIa trial of lead candidate QGC001 in patients with hypertension (high blood pressure).

Download Press Release